Identified the cellular process by which Cisplatin chemotherapy causes neuronal damage

by Hospital Universitari de Bellvitge

4 years ago
cancer, chemotherapy, Cisplatin, neuropathy, peripheral nervous system

Once the mechanism has been described by a team from IDIBELL, ICO, HUB, and UAB, new strategies can be designed to alleviate the adverse effects of Cisplatin, one of the most common drugs in chemoth...

Researchers discover a new method to regulate cell plasticity

by IRB Barcelona - Instituto de Investigación Biomédica

4 years ago
immune system, cancer, cell plasticity, genetics, biomedicine

Researchers at IRB Barcelona’s Cellular Plasticity and Disease Laboratory propose a more efficient way to limit cell plasticity without causing cell damage. The new method sheds light on processe...

Cuatro investigadores del CNIO reciben un total de casi un millón de euros en financiación de la AECC para desarrollar sus proyectos de investigación del cáncer

by CNIO - Centro Nacional de Investigaciones Oncológicas

4 years ago
inmunoterapia, AECC, investigación, cáncer

Óscar Fernández-Capetillo, jefe del Grupo de Inestabilidad Genómica, recibe 300.000 euros para estudiar el potencial de la proteína SETD8 como diana en cáncer. SETD8 se ha relacionado con e...

The AECC finances the implantation of a new cancer model in C. elegans

by Hospital Universitari de Bellvitge

4 years ago
personalized genomic medicine, AECC, cancer, genoma

The IDIBELL group led by Dr. Julián Cerón has received an “Ideas Semilla” grant from the Spanish Association Against Cancer (AECC). These grants are addressed at innovative projects tha...

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

by Ysios Capital

4 years ago
Eir Ventures, Galecto, Clinical Pipeline, fibrosis, cancer, Soleus Capital

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials

Identificada una nueva estrategia para el tratamiento del carcinoma renal de pacientes con VHL

by CIBERER - Centro de Investigación Biomédica en Red de Enfermedades Raras

4 years ago
renal, cáncer, INMUNOTHERCAN, VHL

Un trabajo liderado por la U707 CIBERER que lidera Luisa Botella en el Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC) muestra la acción de dos agentes betabloqueantes en células de...

Maximizing the oncology production process

by Telstar

4 years ago
medicines, aseptic process, cancer, manufacturing processes, oncology

Telstar’s cutting-edge technologies and integrated process equipment & systems covering all the critical phases of the oncology production are designed according to the higher requirements of qualit...

OncoDNA firma un acuerdo de colaboración con la ECPC para el Proyecto de Sensibilización sobre Medicina Personalizada 2020

by OncoDNA

4 years ago
paciente, ECPC, Medicina Personalizada, cáncer

En el contexto actual de desigualdades económicas y sociales existentes en muchos países europeos en relación con la atención del cáncer, es fundamental dar con soluciones accesibles que mejoren ...

El papel de la tecnología en la detección y el tratamiento del cáncer

by Alma Medical Imaging

4 years ago
tecnología, detección, tratamiento, cáncer, nanomedicinaimágen médica, imágen médica, nanomedicina

Hoy, desde Alma Medical Imaging, queremos hablarte del papel de la tecnología en la detección y el tratamiento del cáncer.

The co-occurrence of cancer driver genes, key to precision medicine

by IRB Barcelona - Instituto de Investigación Biomédica

4 years ago
cancer, genes, bioinformatics, precision medicine

Cancer driver genes are those with mutations that are essential for tumour development and spread. Led by ICREA researcher Patrick Aloy, scientists from the Structural Bioinformatics and Network Bi...

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

4 years ago
LAVA Therapeutics, Ysios Capital, cancer, pharmaceutical, platform

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...